AccuTOX from Defence Therapeutics Inc. (CSE: DTC) (FRA: DTC) (OTC: DTCFF) is a clinical-stage molecule being investigated as a potential cancer treatment.
Vancouver, British Columbia–(Newsfile Corp. – February 21, 2023) – Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (“Defence” or the “Company“), a Canadian…
Vancouver, British Columbia–(Newsfile Corp. – February 6, 2023) – Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (“Defence” or the “Company“), a Canadian…
Vancouver, British Columbia–(Newsfile Corp. – February 3, 2023) – Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (“Defence” or the “Company“), a Canadian…
Vancouver, British Columbia–(Newsfile Corp. – January 31, 2023) – Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (“Defence” or the “Company“), a Canadian…
Vancouver, British Columbia–(Newsfile Corp. – December 20, 2022) – Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (“Defence” or the “Company“), a Canadian biopharmaceutical…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
